An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder

References

• Altamura AC, Dell'osso B, D'Urso N, Russo M, Fumagalli S, Mundo E. 2008. Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder. CNS Spectrums 13:415–422.
   PubMedGoogle Scholar
• Ansseau M, Fischler B, Dierick M, Mignon A, Leyman S. 2005. Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study. Eur Psychiatry 20:229–235.
   PubMed Web of Science ®Google Scholar
• Baldwin DS. 2008. Room for improvement in the pharmacological treatment of anxiety disorders. Curr Pharmaceut Design 14:3482–3491.
   PubMedGoogle Scholar
• Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, . 2005. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567–596.
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Waldman S, Allgulander C. 2011. Evidence-based pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol 14:697–710.
   PubMed Web of Science ®Google Scholar
• Bandelow B, Zohar J, Hollander E, Kasper S, Möller H-J; WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders. 2008. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry 9:248–312.
   PubMed Web of Science ®Google Scholar
• Berger A, Mychaskiw M, Dukes E, Edelsberg J, Oster G. 2009. Magnitude of potentially inappropriate prescribing in Germany among older patients with generalized anxiety disorder. BMC Geriatrics 9:31.
   PubMedGoogle Scholar
• Canadian Psychiatric Association, 2006. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 51 (8 Suppl 2):9–91S.
   PubMedGoogle Scholar
• Kessler RC, Andrade LH, Bijl RV, Offord DR, Demler OV, Stein DJ. 2002. The effects of co-morbidity on the onset and persistence of generalized anxiety disorder in the ICPE surveys. International Consortium in Psychiatric Epidemiology. Psychol Med 32:1213–1225.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Brandenburg N, Lane M, Roy-Byrne P, Stang PD, Stein DJ, Wittchen H-U. 2005. Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. Psychol Med 35:1073–1082.
   PubMed Web of Science ®Google Scholar
• Lieb R, Becker E, Altamura C. 2005. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 15:445–452.
   PubMed Web of Science ®Google Scholar
• Munk-Jorgensen P, Allgulander C, Dahl AA, Foldager L 2006. Prevalence of generalized anxiety disorder in general practice in Denmark, Finland, Norway, and Sweden. Psychiatr Serv 57:1738–44.
   PubMed Web of Science ®Google Scholar
• Pollack M. Generalised anxiety disorder: global challenges and solutions. Presented at International Anxiety Disorders Symposium, Cape Town, South Africa, May 1st, 2010.
   Google Scholar
• Salzman C, Goldenberg I, Bruce SE, Keller MB. 2001. Pharmacologic treatment of anxiety disorders in 1989 versus 1996: results from the Harvard/Brown anxiety disorders research program. J Clin Psychiatry 62:149–152.
   PubMedGoogle Scholar
• Sandelin R, Ahnemark E, Kowalski J, Allgulander C. Treatment patterns and costs in patients with generalized anxiety disorder: One year retrospective analysis of data from National Registers in Sweden. Poster # 130 presented at 30th Annual Conference Anxiety Disorders Association of America (ADAA) March 4–7, 2010, Baltimore, MD, USA.
   Google Scholar
• Spitzer RL, Kroenke K, Williams JB, Löwe B. 2006. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Int Med 166:1092–1097.
   PubMed Web of Science ®Google Scholar
• Uhlenhuth EH, Balter MB, Ban TA, Yang K. 1999. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992–1997. Depress Anxiety 9:107–116.
   Google Scholar
• Weiller E, Bisserbe JC, Maier W, Lecrubier Y. 1998. Prevalence and recognition of anxiety syndromes in five European primary care settings. A report from the WHO Study on Psychological Problems In General Health Care. Br J Psychiatr 173 (suppl. 34):18–23.
   Google Scholar
• Wittchen H-U, Jacobi F. 2005. Size and burden of mental disorders in Europe: a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 15:357–376.
   PubMed Web of Science ®Google Scholar
• Wittchen H-U. 2002. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 16:162–171.
   PubMed Web of Science ®Google Scholar
• Wittchen H-U, Carter RM, Pfister H, Montgomery SA, Kessler RC. 2000. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 15:319–328.
   PubMed Web of Science ®Google Scholar
• Wittchen H-U, Kessler RC, Beesdo K, Krause P, Höfler M, Hoyer J. 2002. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 63(Suppl 8):24–34.
   PubMedGoogle Scholar
• Zimmerman M, Chelminski I. 2003. Clinician recognition of anxiety disorders in depressed outpatients. J Psychiatr Res 37:325–333.
   PubMedGoogle Scholar